Xenon Pharmaceuticals (XENE) Research & Development (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Research & Development of $4.2 million for Q1 2026, up 22.66% year-over-year from $3.4 million in Q1 2025, and up 102.09% quarter-over-quarter from -$200.7 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Research & Development (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Research & Development for 14 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 22.66% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 204.78% YoY), while the FY2025 annual figure was $12.5 million, up 11.46% from the prior year.
- Research & Development climbed to $4.2 million in Q1 2026 per XENE's latest filing, from -$200.7 million in the prior quarter.
- Across five years, Research & Development topped out at $77.1 million in Q3 2025 and bottomed at -$200.7 million in Q4 2025.
- Historically, Research & Development has averaged $12.6 million across 5 years, with a median of $29.4 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development soared 164.52% — and 2025, when it slumped 14019.56%.
- Xenon Pharmaceuticals' Research & Development stood at -$63.7 million in 2022, then jumped by 164.52% to $41.1 million in 2023, then slumped by 96.49% to $1.4 million in 2024, then plunged by 14019.56% to -$200.7 million in 2025, then soared by 102.09% to $4.2 million in 2026.
- Business Quant data shows XENE's Research & Development at $4.2 million in Q1 2026, -$200.7 million in Q4 2025, and $77.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 99.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.22 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | -200.72 Mn |
| Sep 30, 2025 | 77.05 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 56.97 Mn |
| Jun 30, 2024 | 49.70 Mn |
| Mar 31, 2024 | 44.25 Mn |
| Dec 31, 2023 | 41.08 Mn |
| Sep 30, 2023 | 42.88 Mn |
| Jun 30, 2023 | 44.04 Mn |
| Mar 31, 2023 | 39.52 Mn |
| Dec 31, 2022 | -63.66 Mn |
| Sep 30, 2022 | 29.43 Mn |
| Jun 30, 2022 | 22.15 Mn |
| Mar 31, 2022 | 19.36 Mn |
| Dec 31, 2021 | 21.89 Mn |
| Sep 30, 2021 | 18.89 Mn |